Premium
Megakaryopoiesis in vitro in myelodysplastic syndromor and development es and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors
Author(s) -
Liu Yin J. A.,
Adams J. A.,
Brereton M. L.,
Hann A.,
Harrison B. D.,
Briggs M.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.01916.x
Subject(s) - megakaryocyte , thrombopoietin , cancer research , myeloid , growth factor , granulocyte macrophage colony stimulating factor , granulocyte colony stimulating factor , myelodysplastic syndromes , medicine , immunology , bone marrow , cytokine , biology , haematopoiesis , stem cell , chemotherapy , microbiology and biotechnology , receptor
Pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF) can stimulate megakaryopoiesis in vitro in some myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) patients. We assessed PEG‐rHuMGDF combined with granulocyte colony‐stimulating factor (G‐CSF), granulocyte–macrophage CSF (GM‐CSF), interleukin 3 (IL‐3), IL6, stem cell factor (SCF) or erythropoietin in 40 MDS, 33 AML and 16 normal bone marrow samples. CD61‐positive cells in suspension cultures increased with PEG‐rHuMGDF alone in 20/25 RA + RAS, 11/14 RAEB + RAEBt and 29/33 AML cases. Further increases when IL‐3 and/or SCF were added to PEG‐rHuMGDF occurred in 14/20 RA + RAS, 8/13 RAEB + RAEBt and 18/26 AML cases. CFU‐Mk growth was poor overall, but could be enhanced by PEG‐rHuMGDF combinations in some patients. Stimulation of megakaryopoiesis by PEG‐rHuMGDF can be augmented by IL‐3 and SCF in many MDS and AML patients.